Healthcare Industry News: Diabetic Foot Ulcer
News Release - February 28, 2011
Derma Sciences Receives FDA Clearance for MEDIHONEY(R) GelFourth Product in MEDIHONEY Franchise Will Expand Market and Strengthen Brand Leadership Position
PRINCETON, N.J.--(Healthcare Sales & Marketing Network)-- Derma Sciences, Inc. (Nasdaq:DSCI ), a medical device and pharmaceutical company focused on advanced wound care, today announced receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Company’s patent-pending MEDIHONEY® Gel Wound and Burn Dressing. This latest MEDIHONEY line extension is dispensed from a tube and is comprised of Active Manuka (Leptospermum) honey blended with natural-based gelling agents. This is the fourth product in the expanding MEDIHONEY franchise, and will be launched into the market by the Company’s 20-person U.S. sales force at the major annual wound conferences this spring.
Commenting on the clearance, Edward J. Quilty, Derma Sciences’ President and Chief Executive Officer said, “This is an important addition to our MEDIHONEY product offering and we expect the marketplace to embrace this new product as we strengthen our category leadership. MEDIHONEY Gel will provide clinicians and patients with added versatility in their use of honey-based products for challenging wounds and burns. Because the product is blended with gelling agents, the honey is able to better maintain its physical integrity at the site of the wound, even in the presence of wound fluid and body heat. This will make for a more durable and lasting product, which is key in the management of chronic wounds. Importantly, its proprietary formulation utilizing natural gelling agents has a patent pending in the U.S., which if granted, will further increase our IP around the MEDIHONEY brand.”
The new MEDIHONEY Gel will be manufactured by Derma Sciences in its facility in Toronto.
About Derma Sciences, Inc.
Derma Sciences is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care products, advanced wound care dressings and traditional dressings. Derma Sciences has successfully completed the treatment phase of a Phase 2 clinical trial in Diabetic Foot Ulcer healing with DSC127, a novel pharmaceutical drug under development for accelerated wound healing and scar reduction. Its MEDIHONEY® product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale, randomized controlled trial involving 108 subjects with leg ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudate, and BIOGUARD® for infection prevention. For more information please visit www.dermasciences.com.
Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release or that are otherwise made by or on behalf of the Company. Factors that may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include but are not limited to, those discussed in the Company's filings with the U.S. Securities and Exchange Commission.
Source: Derma Sciences
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.